Top Page
Allergy Therapeutics
(LSE:AGY)
Allergy Therapeutics (AGY) vs. iShares MSCI United Kingdom ETF (EWC)
Allergy Therapeutics Business Overview & Revenue Model
Allergy Therapeutics Financial Statement Overview
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 55.04M | 55.20M | 59.59M | 72.77M | 84.33M |
| Gross Profit | 25.13M | 29.74M | 32.69M | 48.95M | 61.80M |
| EBITDA | -29.43M | -30.74M | -36.24M | -8.69M | 7.61M |
| Net Income | -40.13M | -40.22M | -43.07M | -13.78M | 2.89M |
Balance Sheet | |||||
| Total Assets | 67.54M | 64.83M | 66.77M | 72.95M | 88.09M |
| Cash, Cash Equivalents and Short-Term Investments | 12.79M | 12.91M | 14.85M | 20.52M | 40.27M |
| Total Debt | 60.09M | 30.99M | 35.99M | 10.53M | 11.17M |
| Total Liabilities | 95.74M | 61.12M | 64.70M | 35.18M | 39.55M |
| Stockholders Equity | -28.19M | 3.71M | 2.07M | 37.77M | 48.53M |
Cash Flow | |||||
| Free Cash Flow | -31.98M | -35.54M | -35.59M | -17.17M | 5.95M |
| Operating Cash Flow | -28.72M | -32.14M | -30.92M | -14.11M | 8.52M |
| Investing Cash Flow | -3.15M | -1.20M | -4.67M | -3.06M | -2.76M |
| Financing Cash Flow | 32.04M | 31.43M | 29.91M | -2.64M | -2.03M |
Allergy Therapeutics Technical Analysis
Allergy Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £193.33M | -7.90 | 2.83% | 2.18% | 8.74% | -166.50% | |
65 Neutral | £84.77M | ― | ― | ― | ― | ― | |
63 Neutral | £104.17M | -5.24 | -396.71% | ― | 93.48% | 51.18% | |
59 Neutral | £2.75B | 9.50 | 15.66% | 4.16% | 3.73% | 27.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | £747.24M | -14.05 | ― | ― | -0.28% | 22.94% |
Allergy Therapeutics Corporate Events
Allergy Therapeutics will present new clinical and biomarker data from its pollen and food-allergy research pipeline at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia. The company emphasised that no new price-sensitive information will be disclosed at the event.
The group is highlighting Phase III results for its Grass MATA MPL short-course subcutaneous immunotherapy, including a statistically significant 22.5% reduction in symptom and medication scores versus placebo and favourable safety data in a paediatric trial cohort. It will also showcase positive safety, tolerability and interim biomarker data from its VLP Peanut Phase I/IIa trial, underlining the versatility of its platform and reinforcing its positioning in disease-modifying therapies following recent regulatory approval of Grass MATA MPL in Germany.
The most recent analyst rating on (GB:AGY) stock is a Sell with a £11.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has amended its existing loan agreement with Hayfin, replacing an uncommitted £20m line with a new committed £40m senior secured facility, giving the company £60m of total debt and at least 12 months of working capital. The funding is intended to support operations, the proposed Hong Kong listing and growth initiatives anchored by the German launch of Grassmuno, while simplifying the capital structure by eliminating shareholder debt.
As part of the deal, Hayfin has exercised all previously issued warrants and new subscription rights on a cashless basis, receiving 191,089,599 new shares and ending up with a 3.02% stake in the company. Following admission of these shares to AIM, Allergy Therapeutics’ issued share capital will rise to 6,332,529,550 shares, clarifying the new voting rights base for investors and slightly diluting existing shareholders as the company secures long‑term financing.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £9.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has strengthened its leadership and governance structure with the appointment of veteran investment banker Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and healthcare finance specialist Lawrence Allen Wang as an Independent Non-Executive Director. The newly created CSO role will spearhead the company’s long-term international growth strategy, corporate development and partnership agenda as it advances its next-generation allergy pipeline and seeks to build on its established positions in core markets. Together, the appointments deepen the board’s investment and healthcare expertise and are intended to support Allergy Therapeutics’ ambition to become a global leader in allergy treatments, including potential plans for a dual listing on the Hong Kong Stock Exchange, signalling an intensified focus on international expansion and access to Asian capital markets.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £11.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics plc reported that all resolutions at its 2026 Annual General Meeting were passed on a show of hands, reflecting strong shareholder backing for the company’s governance and strategic direction. Shareholders approved the 2025 accounts, the directors’ remuneration report, the election of new board members Helge Weiner-Trapness and Lawrence Allen Wang, and the re-election of existing directors, alongside the reappointment of BDO LLP as auditors. They also granted the board authority to allot shares and equity securities and approved amendments to the Articles of Association, providing the company with continued financial and operational flexibility to support its growth plans within the allergy immunotherapy market.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has granted new share options under its long-term incentive plan to key members of its management team, including CEO Manuel Llobet and CFO Shaun Furlong, as part of a strategy to drive long-term value creation and align leadership incentives with shareholder interests. The options, which vest over three years based on adjusted EBITDA and share price performance, increase total outstanding options to 365.2 million shares, or 5.95% of current issued share capital, underscoring the company’s use of performance-linked equity to support its future growth plans and maintain alignment with broader stakeholder outcomes.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics reported a strong first half to its 2026 financial year, with revenues rising 7% to £36.3 million despite the ongoing phase-out of older unregistered products in Germany under the TAV programme, underlining renewed growth in its registered portfolio in its largest market. The company secured German marketing authorisation for Grassmuno, the first new subcutaneous grass pollen immunotherapy launch in that market in two decades and the first such product approved under TAV, and has begun commercialisation from January 2026, positioning it to benefit as competing products that fail to meet regulatory standards are withdrawn. The group ended December with £10.1 million in cash after using £55 million of warrant proceeds from shareholder lenders to repay all outstanding debt to them, significantly strengthening its balance sheet while retaining access to up to £70 million in uncommitted facilities and continuing to evaluate a potential dual primary listing in Hong Kong, moves that collectively support its growth strategy and ongoing R&D programmes, including its peanut allergy vaccine and paediatric development of Grassmuno.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has published the notice of its 2025 Annual General Meeting, following release of its annual report and accounts for the year ended 30 June 2025, with meeting documents now available to shareholders via the company’s website. The company is asking shareholders to approve the appointment of two new board members, former HSBC vice chairman Helge Weiner-Trapness as executive director and chief strategy officer, and Adicon CFO Lawrence Allen Wang as a non-executive director, both bringing substantial investment banking and healthcare experience in Asia. Management believes these additions will support Allergy Therapeutics’ exploration of a potential dual primary listing on the Hong Kong Stock Exchange alongside its AIM quote and underpin its strategy to expand in Asia and strengthen its position as a global player in allergy treatments.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has secured shareholder approval at its general meeting to allot up to 610 million new ordinary shares, representing around 10% of its existing share capital, and to disapply pre-emption rights, giving the board flexibility to conduct a non-pre-emptive equity raise via private placements if it chooses to proceed. While no terms, investors or pricing have yet been agreed and there is no certainty a fundraise will occur, any proceeds would support the company’s strategy to advance treatments for grass and peanut allergies, bolster working capital, and prepare for a planned dual listing in Hong Kong; the company also confirmed it has posted its annual report for the year to 30 June 2025 and made it available on its website.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £12.00 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno®. This approval marks the first of its kind under Germany’s TAV programme and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The approval is a pivotal moment for the company, validating its MATA MPL platform and supporting its expansion strategy into other global markets. Grassmuno® offers a convenient, short-course treatment option for grass pollen allergies, potentially driving business growth in Germany, the company’s largest market.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has received marketing authorization from the Paul Ehrlich Institut in Germany for its innovative subcutaneous grass pollen allergen immunotherapy, Grassmuno. This approval marks the first of its kind under Germany’s TAV program and is expected to significantly impact the German seasonal allergy market, projected to reach approximately US$1 billion by 2030. The company plans to commercialize Grassmuno in Germany by Q1 2026 and is exploring further regulatory submissions in other global markets. This development is seen as a pivotal moment for Allergy Therapeutics, reinforcing its commitment to clinical excellence and expanding its market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics has announced plans for a potential equity raise by issuing new shares to facilitate its dual listing on the Hong Kong Stock Exchange, expected in the first half of 2026. The company is seeking shareholder approval to issue up to 610 million new shares, which will support its strategy of developing treatments for grass and peanut allergies and address general corporate needs. The outcome of the equity raise remains uncertain, as no agreements with investors have been finalized.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenue remaining flat at £55.0m due to the transition to fully licensed products in Germany. The company strengthened its financial position through strategic investments, securing a new £50m shareholder loan facility, and exploring a dual primary listing in Hong Kong. Progress in R&D was highlighted by advancements in the Grass MATA MPL and VLP Peanut PROTECT trials, positioning the company for future growth and increased market presence.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.
Allergy Therapeutics announced that its Phase I/IIa PROTECT trial has successfully met its primary safety endpoint at the highest planned treatment dose. Preliminary safety data from 48 participants, including both peanut-allergic and healthy individuals, demonstrated that a 2000-fold increase in dose was safe and well tolerated. The trial’s results support the safety and efficacy of the VLP Peanut treatment, with preparations underway for a Phase IIb trial. This milestone reinforces the company’s confidence in its short-course approach and positions it well for further clinical development.
The most recent analyst rating on (GB:AGY) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Allergy Therapeutics stock, see the GB:AGY Stock Forecast page.